218 related articles for article (PubMed ID: 21649790)
1. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of administering abobotulinumtoxinA through a single injection point when treating lateral periocular rhytides.
Kiripolsky MG; Goldman MP
J Cosmet Dermatol; 2011 Sep; 10(3):232-4. PubMed ID: 21896136
[TBL] [Abstract][Full Text] [Related]
3. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
4. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.
Sepehr A; Chauhan N; Alexander AJ; Adamson PA
Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497
[TBL] [Abstract][Full Text] [Related]
6. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study.
Allen SB; Goldenberg NA
Dermatol Surg; 2012 Jun; 38(6):867-70. PubMed ID: 22268727
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes.
Carruthers J; Carruthers A; Monheit GD; Davis PG
Dermatol Surg; 2010 Dec; 36 Suppl 4():2135-45. PubMed ID: 21070457
[TBL] [Abstract][Full Text] [Related]
8. A two-center, open-label, randomized, split-face study to assess the efficacy and safety of one versus three intradermal injection sites of abobotulinumtoxinA in the treatment of lateral periocular rhytides.
Fabi SG; Sundaram H; Guiha I; Goldman MP
J Drugs Dermatol; 2013 Aug; 12(8):932-7. PubMed ID: 23986168
[TBL] [Abstract][Full Text] [Related]
9. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
Kapoor R; Shome D; Jain V; Dikshit R
Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
[TBL] [Abstract][Full Text] [Related]
10. Retrospective review of 500 patients treated with abobotulinumtoxinA.
Hevia O
J Drugs Dermatol; 2010 Sep; 9(9):1081-4. PubMed ID: 20865838
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of headache relief with cosmetic onabotulinumtoxinA injections.
Goldman ND; Dorton LH; Marcum KK; Gilbert RM; Sandoval LF
J Cosmet Dermatol; 2014 Sep; 13(3):224-31. PubMed ID: 25196690
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox(®) ) or abobotulinumtoxinA (Dysport(®) ) make a difference?
Ravindra P; Jackson BL; Parkinson RJ
BJU Int; 2013 Jul; 112(1):94-9. PubMed ID: 23490404
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Facial Aesthetic Treatment Over Five or More Years: A Retrospective Cross-sectional Analysis of Continuous OnabotulinumtoxinA Treatment.
Carruthers A; Sadick N; Brandt F; Trindade de Almeida AR; Fagien S; Goodman GJ; Raspaldo H; Smith K; Darmody S; Gallagher CJ; Street J; Romagnano L
Dermatol Surg; 2015 Jun; 41(6):693-701. PubMed ID: 25973559
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines.
Cohen JL; Dayan SH; Cox SE; Yalamanchili R; Tardie G
Dermatol Surg; 2012 Sep; 38(9):1497-505. PubMed ID: 22621180
[TBL] [Abstract][Full Text] [Related]
16. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G
Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044
[TBL] [Abstract][Full Text] [Related]
17. The South American Glabellar Experience Study (SAGE): a multicenter retrospective analysis of real-world treatment patterns following the introduction of incobotulinumtoxinA in Argentina.
Banegas RA; Farache F; Rancati A; Chain M; Gallagher CJ; Chapman MA; Caulkins CA
Aesthet Surg J; 2013 Sep; 33(7):1039-45. PubMed ID: 23990584
[TBL] [Abstract][Full Text] [Related]
18. Time to onset of response of abobotulinumtoxina in the treatment of glabellar lines: a subset analysis of phase 3 clinical trials of a new botulinum toxin type A.
Schlessinger J; Monheit G; Kane MA; Mendelsohn N
Dermatol Surg; 2011 Oct; 37(10):1434-42. PubMed ID: 21745254
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact.
Jandhyala R
J Plast Reconstr Aesthet Surg; 2012 Jun; 65(6):720-31. PubMed ID: 22225675
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3 Commercially Available Botulinum Toxin Neuromodulators on Facial Synkinesis: A Randomized Clinical Trial.
Thomas AJ; Larson MO; Braden S; Cannon RB; Ward PD
JAMA Facial Plast Surg; 2018 Mar; 20(2):141-147. PubMed ID: 28973094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
